<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02489526</url>
  </required_header>
  <id_info>
    <org_study_id>VVZ149-POP-P2-US001</org_study_id>
    <nct_id>NCT02489526</nct_id>
  </id_info>
  <brief_title>Evaluate the Analgesic Efficacy and Safety of VVZ-149 Injections for Post-Operative Pain Following Colorectal Surgery</brief_title>
  <official_title>A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Analgesic Efficacy and Safety of VVZ-149 Injections for Post-Operative Pain Following Laparoscopic Colorectal Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vivozon, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vivozon, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this Phase 2 study is to evaluate the efficacy and safety of an analgesic drug&#xD;
      candidate, VVZ-149 Injections. The study is designed as randomized, double-blind, parallel,&#xD;
      placebo-controlled study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      VVZ-149 is a dual antagonist of GlyT2 and 5HT2A. GlyT2 blockage increases inhibitory synaptic&#xD;
      transmission by glycine in the spinal cord, resulting in a reduction of pain transmissions to&#xD;
      the brain. 5HT2A blockage decreases descending serotonergic facilitatory modulation on pain&#xD;
      transmission by the brain and reduces nociceptor activation in peripheral nerves, which are&#xD;
      primary sources of pain in post-surgical pain. VVZ-149 has been shown to have comparable&#xD;
      efficacy to morphine in well controlled (blind, complete randomization with a positive&#xD;
      control) animal studies using rat models of post-operative pain and formalin-induced pain.&#xD;
      The PK/PD study in animals indicates that therapeutic plasma concentration in human subjects&#xD;
      will be 600-1,900 ng/ml. A clinical Phase 1 study performed in healthy subjects has shown no&#xD;
      clinically significant adverse events up to a plasma concentration level of 3,261 ng/ml other&#xD;
      than brief symptoms of mild nausea or dizziness, and mild somnolence when the plasma exposure&#xD;
      level is more than 2,000 ng/ml.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 28, 2015</start_date>
  <completion_date type="Actual">August 15, 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sum of Pain Intensity Difference over 8-hours post-dose (SPID8)</measure>
    <time_frame>8 hours post-dose</time_frame>
    <description>SPID8 using Numerical Pain Rating Scale (NRS, 0-10) measured up to 8 hours post-dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference of Opioid Consumption between Study Groups</measure>
    <time_frame>0-2, 2-4, 4-6, 6-8, 8-12, 12-16, and 16-24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Pain Intensity (NRS)</measure>
    <time_frame>9 and 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Pain Relief (PR) assessed using a 6-point categorical scale</measure>
    <time_frame>9 and 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Global Measurement of Subject Satisfaction between Study Groups</measure>
    <time_frame>8 and 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Richmond Agitation-Sedation Scale</measure>
    <time_frame>9 and 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Incidence of Postoperative Nausea and Vomiting</measure>
    <time_frame>8 and 24 hours post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Post-Operative Pain</condition>
  <arm_group>
    <arm_group_label>VVZ-149 Injections</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VVZ-149 Injections</intervention_name>
    <description>Experimental group will receive a loading dose of 1.8 mg/kg VVZ-149 intravenous infusion for 0.5 hour followed by a maintenance dose of 1.3 mg/kg/h VVZ-149 intravenous infusion for 7.5 hours.</description>
    <arm_group_label>VVZ-149 Injections</arm_group_label>
    <other_name>Opiranserin Injections</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo group will receive the corresponding amount of placebo.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men and women age between 18-70, inclusive.&#xD;
&#xD;
          2. Pain intensity (NRS) ≥4 at initial post-operative measurement in PACU.&#xD;
&#xD;
          3. Subjects undergoing planned laparoscopic colorectal surgery.&#xD;
&#xD;
          4. Ability to provide written informed consent.&#xD;
&#xD;
          5. Ability to understand study procedures and communicate clearly with the investigator&#xD;
             and staff.&#xD;
&#xD;
          6. American Society of Anesthesiologists (ASA) risk class of I to III.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        &lt; Surgical Factors &gt;&#xD;
&#xD;
          1. Emergency or unplanned surgery.&#xD;
&#xD;
          2. Repeat operation (e.g., previous surgery within 30 days for same condition).&#xD;
&#xD;
          3. Cancer-related condition causing preoperative pain in site of surgery.&#xD;
&#xD;
             &lt; Subject Characteristics &gt;&#xD;
&#xD;
          4. Women with childbearing potential (Women age 18-55 must undergo pregnancy test).&#xD;
&#xD;
          5. Women who are pregnant or breastfeeding.&#xD;
&#xD;
          6. Chronic pain diagnosis (e.g., ongoing pain at baseline with NRS ≥ 4/10).&#xD;
&#xD;
          7. Unstable or poorly controlled psychiatric condition (e.g., untreated PTSD, anxiety, or&#xD;
             depression) Subjects who take stable doses (same dose &gt;30 days) of antidepressants and&#xD;
             anti-anxiety drugs may be included.&#xD;
&#xD;
          8. Unstable or acute medical condition (e.g., unstable angina, congestive heart failure,&#xD;
             renal failure, hepatic failure, AIDS).&#xD;
&#xD;
             &lt; Drug, Alcohol, and Pharmacological Considerations &gt;&#xD;
&#xD;
          9. Renal or hepatic impairment.&#xD;
&#xD;
         10. History of alcohol, opiate or other drug abuse or dependence within 12 months prior to&#xD;
             Screening (TICS alcohol/drug screen will be performed at Screening).&#xD;
&#xD;
         11. Ongoing or recent (within 30 days prior to surgery) use of steroids, opioids, or&#xD;
             antipsychotics.&#xD;
&#xD;
         12. Alcohol consumption within 24 hours of surgery.&#xD;
&#xD;
         13. Use of nonsteroidal anti-inflammatory drugs (NSAIDs) or acetaminophen within 24 hours&#xD;
             of surgery.&#xD;
&#xD;
         14. Use of herbal agents or nutraceuticals (i.e., chaparral, comfrey, germander, jin bu&#xD;
             huan, kava, pennyroyal, skullcap, St. John's wort, or valerian) within 7 days prior to&#xD;
             surgery.&#xD;
&#xD;
             &lt; Anesthetic and Other Exclusion Considerations &gt;&#xD;
&#xD;
         15. Use of neuraxial or regional anesthesia related to the surgery.&#xD;
&#xD;
         16. Use of local anesthetic wound infiltration &gt; 20 ml of 1% lidocaine&#xD;
&#xD;
         17. Use of ketamine, gabapentin, pregabalin, or lidocaine (&gt;1 mg/kg) intra or&#xD;
             peri-operatively, or within 24 hours of surgery.&#xD;
&#xD;
         18. Subjects with known allergies to hydromorphone.&#xD;
&#xD;
         19. Subjects who received another investigational drug within 30 days of scheduled&#xD;
             surgery.&#xD;
&#xD;
         20. Subjects who have long PR (&gt;200 msec) or prolonged QTc (&gt; 450 msec) at Screening or on&#xD;
             an EKG done immediately prior to dosing.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>June 18, 2015</study_first_submitted>
  <study_first_submitted_qc>June 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 3, 2015</study_first_posted>
  <disposition_first_submitted>August 11, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>August 18, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">August 25, 2020</disposition_first_posted>
  <last_update_submitted>August 18, 2020</last_update_submitted>
  <last_update_submitted_qc>August 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

